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In this first issue of Intensive Care Medicine Experimental, two related studies describe
the effects of antibodies directed against adrenomedullin (ADM), a vasoactive peptide
that is released from various tissues during systemic inflammation, in murine sepsis.
ADM, derived from a larger precursor peptide (pro-ADM), is released into the circu-
lation during systemic inflammation, and the highest plasma concentrations are mea-
sured in patients with septic shock [1]. With a plasma half-life of approximately
20 min, it exerts multiple effects of which the most relevant appears to be vasodilation
[2]. The consequent clinical sequelae of increased ADM concentrations are far from
clear. While elevated ADM levels are associated with impaired outcome in sepsis pa-
tients [1] and the measurement of the circulating pro-peptide of ADM might serve as
a marker to assess disease severity and predict mortality [3], administration of exogen-
ous ADM actually improved outcome in animal models of septic shock [4].
Intriguingly, in this issue of Intensive Care Medicine Experimental, two studies dem-
onstrate beneficial effects of anti-ADM antibodies administered in a murine cecal
ligation and puncture (CLP) model [5,6]. These studies represent the first attempts at
antibody targeting of the ADM cascade in vivo. Struck et al. [5] describe the develop-
ment of monoclonal antibodies directed against various epitopes of ADM and their
ability to attenuate sepsis-induced mortality in severe murine sepsis (100% control
group mortality within 2 to 3 days). The severity of this model means that any long-
term deleterious or beneficial effects of the antibody remain unknown. Notably, all
antibodies directed against ADM improved survival. Of interest, the antibody against
the N-terminal moiety of ADM prevented mortality most effectively, while it inhibited
ADM agonistic activity by only 25%. Wagner et al. [6] performed a more mechanistic
study into the effects of HAM1101, the antibody targeted against the N-terminal part
of ADM, in a resuscitated murine CLP model. They show that HAM1101 improves
vasoactive responsiveness to catecholamines, attenuates systemic inflammation, and
improves kidney function. The beneficial effects on the kidneys are likely attributable
to reduced iNOS expression and nitrotyrosine formation in HAM1101-treated animals.
The effects on inflammatory parameters are surprising as ADM itself has also been
reported to inhibit inflammation [7]. In summary, previous work has established that
high endogenous levels of ADM correlate with poor outcomes and that exogenous
administration improved outcomes, while now it is reported that antagonism of ADM
using antibodies improves outcome in an animal sepsis model.
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How can we explain these apparently conflicting results? We naturally tend to prefer
simple linear reasoning. However, reality, especially in the case of (patho)physiology, is
more complex. ADM-mediated effects appear to represent yet another example of this
fact. Timing and the magnitude of increase in ADM may be especially relevant in un-
derstanding its clinical effects in sepsis. In this respect, it is important to recognize that
Struck et al. found that the least efficacious antibody in terms of antagonistic activity
exerted the largest beneficial effect on survival. One could argue that other non-ADM-
dependent effects of the antibody may play a role. However, it could also indicate that
only very high concentrations of ADM exert deleterious effects, while modest increases
of this peptide are beneficial. In addition to concentration-dependent and time-
dependent effects, the specific clinical condition of sepsis, e.g., hyper- vs hypodynamic
sepsis, is also likely to play a role in the observed discrepancies. It is clear that the path
to clinical relevance at the bedside is long and bumpy, and based on the above
described results, it is already clear that in sepsis patients, it will be a difficult task
to define the therapeutic window of opportunity to modulate the ADM pathway.
Nevertheless, further investigation of the effects of modulating this pathway is clearly
warranted.
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